Serina names Trevi executive Farrell Simon to board, days after amending CEO's pay pact

Serina Therapeutics disclosed two related corporate actions in late July 2026. On July 19, 2026, the company and its subsidiary Serina Therapeutics (AL), Inc. entered into an Amended and Restated Employment Agreement with Steve Ledger, the Company's Chief Executive Officer.¹ The new agreement provides Ledger an annual base salary of $500,000 and eligibility for a target annual bonus equal to 50% of his base salary based on annual goals set by the Board.¹

The agreement also sets severance terms. If Ledger is terminated without Cause or resigns for Good Reason outside a Change in Control, he would receive 12 months of base salary plus a pro-rated annual bonus, paid in a lump sum within 60 days, along with up to 12 months of COBRA premium reimbursement.¹ In a qualifying termination tied to a Change in Control, he would instead receive 1.5 times base salary, 1.5 times target bonus, a pro-rated bonus, up to 18 months of COBRA reimbursement, and full accelerated vesting of unvested time-based equity awards.¹

Three days later, on July 22, 2026, Serina announced a board addition. The company appointed Farrell Simon, Pharm. D., to its Board of Directors, effective immediately.² Simon will also serve on the Board's Audit and Compensation Committees.² He currently serves as Chief Commercial Officer at Trevi Therapeutics, Inc., where he leads commercial strategy, lifecycle management, and pre-commercial readiness planning.² During his tenure at Trevi, he helped engage the company's investor base and supported financings totaling more than $400 million from investors including Frazier, Vivo, Venrock, and Viking.²

The announcement referenced Serina's lead program. The SER-252-1b study is a randomized, double-blind, placebo-controlled Phase 1b trial with single-ascending-dose cohorts totaling 40 patients and multiple-ascending-dose cohorts totaling up to 48 patients in adults with Parkinson's disease and motor fluctuations.²